Phase II Results for Cabozantinib in RET-Rearranged Lung Cancer

August 14, 2017
Christine M. Lovly, MD, PhD

Christine M. Lovly, MD, PhD, assistant professor of medicine (hematology/oncology), assistant professor of cancer biology, medical oncologist, Vanderbilt-Ingram Cancer Center, discusses phase II results for cabozantinib (Cabometyx) in patients with RET-rearranged lung cancer.